BioDrugsPub Date : 2026-11-13DOI: 10.1007/s40259-026-00818-5
Martina Battistini, Laura Lagostena, Dario Balestra, Mirko Pinotti, Debora Baroni
{"title":"Antisense Oligonucleotides as Quantitative Modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): A Threshold-Based Therapeutic Framework for Class I and Class V CFTR Mutations.","authors":"Martina Battistini, Laura Lagostena, Dario Balestra, Mirko Pinotti, Debora Baroni","doi":"10.1007/s40259-026-00818-5","DOIUrl":"https://doi.org/10.1007/s40259-026-00818-5","url":null,"abstract":"<p><p>Cystic fibrosis is a life-shortening autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Small-molecule modulators have substantially improved outcomes in patients with CFTR folding or gating defects. However, individuals carrying class I nonsense mutations or severe class V splicing variants often remain poorly responsive. In these genetic conditions, the main therapeutic limitation is quantitative: there is insufficient CFTR substrate for correctors or potentiators to act effectively. Antisense oligonucleotides (ASOs) are RNA-targeted agents that can increase the pool of CFTR transcripts available for translation by promoting splice correction, inducing exon skipping or selectively modulating nonsense-mediated messenger RNA decay. Although these mechanisms differ, they converge on a common goal: increasing CFTR expression to a functionally relevant and pharmacologically responsive range. This review proposes a threshold-based framework for ASO development in cystic fibrosis. Within this model, ASOs primarily increase CFTR quantity, whereas correctors, potentiators, stabilisers, enhancers and related small molecules improve CFTR quality by acting on folding, trafficking, gating, conductance or membrane stability. The therapeutic aim is not complete molecular normalisation, but functional sufficiency. By raising CFTR abundance above a minimal functional threshold, ASOs may prime selected class I and class V genotypes for subsequent pharmacological modulation and extend precision treatment to patients who currently remain outside the effective range of approved CFTR modulators.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioDrugsPub Date : 2026-11-01Epub Date: 2026-09-14DOI: 10.1007/s40259-026-00806-9
Fernando de Mora, Vicente Merino-Bohórquez, Rosario García-Vicuña, Isabel Río-Álvarez
{"title":"Biosimilars: A Virtuous Cycle of Sustainability and Innovation.","authors":"Fernando de Mora, Vicente Merino-Bohórquez, Rosario García-Vicuña, Isabel Río-Álvarez","doi":"10.1007/s40259-026-00806-9","DOIUrl":"10.1007/s40259-026-00806-9","url":null,"abstract":"<p><p>A biosimilar is a biological medicinal product developed to replicate a licensed originator-i.e., the reference product-with which it shares quality, efficacy, and safety. Marketed following expiry of the reference product's patent protection, biosimilars introduce competition that benefits patients and foster sustainability. In addition to such sustainability of healthcare systems, biosimilars confer a less widely recognized yet equally important benefit: they stimulate innovation. The European regulatory framework, pioneered by the European Medicines Agency and reinforced by other reference regulatory bodies, has unlocked this innovative potential. This paper examines how the development, manufacturing, commercialization, and clinical use of biosimilars generate advances in healthcare delivery. Drawing on available evidence and market experience, it proposes a classification of biosimilar-driven innovation into three domains: pharmaceutical innovation, technological innovation, and therapeutic innovation. Benefits wholly or partially attributable to biosimilars encompass both incremental and disruptive improvements within each domain. These include, for instance, the reinvestment of resources into novel therapies and technologies; therapeutic paradigm shifts supported by evidence and increasingly reflected in clinical guidelines; and enhanced formulations and delivery devices. Although relevant to all healthcare stakeholders, this paper is primarily directed at physicians. As key facilitators of biosimilar adoption, they will find that the innovative aspects of these medicines offer both compelling arguments to support broader prescribing and practical examples of how biosimilars can enhance clinical practice and improve patient outcomes.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"995-1005"},"PeriodicalIF":8.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148965917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioDrugsPub Date : 2026-11-01Epub Date: 2026-09-14DOI: 10.1007/s40259-026-00804-x
Liyan Qiu, Jonas Torbjörn Ungerbäck, Eric Paul Bennett, Rasmus O Bak
{"title":"Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases.","authors":"Liyan Qiu, Jonas Torbjörn Ungerbäck, Eric Paul Bennett, Rasmus O Bak","doi":"10.1007/s40259-026-00804-x","DOIUrl":"10.1007/s40259-026-00804-x","url":null,"abstract":"<p><p>Lysosomal storage diseases (LSDs) are a group of rare inherited metabolic disorders characterized by lysosomal dysfunction and progressive accumulation of undegraded substrates, leading to multisystem involvement and, in many cases, severe neurodegeneration. Because the blood-brain barrier (BBB) restricts central nervous system (CNS) access for most therapeutic modalities, neurological manifestations remain the major unmet need across LSDs. In this review, we summarize current and emerging strategies aimed at correcting CNS pathology, including enzyme replacement therapy (ERT), adeno-associated virus (AAV)-mediated gene therapy, allogeneic hematopoietic stem cell transplantation (HSCT), and autologous HSCT with gene-modified hematopoietic stem cells. While ERT provides limited CNS benefits and allogeneic HSCT mitigates neurodegeneration only partially, their overall impact on CNS outcomes remains restricted. Newer approaches, such as BBB-shuttling ERTs, CNS-tropic AAV capsids, and genetically modified autologous hematopoietic stem and progenitor cells capable of sustained supraphysiological enzyme production, offer promising avenues for enhanced CNS delivery and cross-correction. Together, these advances underscore a shift toward integrated therapeutic strategies that combine systemic and CNS-directed interventions, with the potential to transform outcomes for patients with LSDs and other neurodegenerative disorders amenable to cross-correction.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"979-993"},"PeriodicalIF":8.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioDrugsPub Date : 2026-11-01Epub Date: 2026-09-17DOI: 10.1007/s40259-026-00807-8
Aisling McGuigan
{"title":"HLX11: A Pertuzumab Biosimilar.","authors":"Aisling McGuigan","doi":"10.1007/s40259-026-00807-8","DOIUrl":"10.1007/s40259-026-00807-8","url":null,"abstract":"<p><p>HLX11 (pertuzumab-dpzb in the USA), marketed as POHERDY<sup>®</sup> in the USA and EU and as HANBEIYOU<sup>®</sup> in China, is a biosimilar of reference pertuzumab, an anti-human epidermal growth factor 2 (HER2) monoclonal antibody. It is approved for use in the same indications as reference pertuzumab: early or metastatic HER2-positive breast cancer. The physicochemical and functional properties of HLX11 are similar to reference pertuzumab, and pharmacokinetic equivalence has been shown in healthy individuals. HLX11 demonstrated equivalent clinical efficacy to EU-sourced reference pertuzumab in the neoadjuvant treatment of patients with HER2-positive, hormone-receptor negative, early stage or locally advanced breast cancer. The tolerability, safety and immunogenicity profiles of the two agents were also similar. No new safety or immunogenicity concerns were observed following a switch from neoadjuvant reference pertuzumab to adjuvant HLX11. The role of reference pertuzumab in the management of HER2-positive breast cancer is well established, and HLX11 provides an effective biosimilar alternative for patients requiring pertuzumab therapy.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"1087-1091"},"PeriodicalIF":8.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioDrugsPub Date : 2026-11-01Epub Date: 2026-09-17DOI: 10.1007/s40259-026-00811-y
Qiang Chen
{"title":"Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.","authors":"Qiang Chen","doi":"10.1007/s40259-026-00811-y","DOIUrl":"10.1007/s40259-026-00811-y","url":null,"abstract":"<p><p>Protein-based therapeutics have transformed modern disease treatment and now constitute a rapidly expanding segment of the pharmaceutical market. In this context, plant-based expression systems have emerged as a versatile alternative to conventional mammalian cell platforms for the production of recombinant proteins. Beyond their well-established advantages in cost, scalability, and biosafety, recent advances in transient expression technologies and plant cell culture systems have enabled rapid, high-yield production of complex biologics with increasing control over product quality. In particular, deconstructed viral vectors and Agrobacterium-mediated transient expression in plants enable rapid recombinant protein production, supporting their potential for applications requiring flexible and accelerated manufacturing. Concurrently, progress in host glycoengineering has enabled the generation of humanized and functionally tailored glycoforms, including antibody glycovariants with enhanced Fc-mediated effector functions. These advances have expanded the applicability of plant-based platforms to the production of monoclonal antibodies, antibody fragments, and emerging antibody-based modalities. In parallel, a broad range of single-chain therapeutic proteins, including enzymes, antimicrobial and antiviral agents, and proteins for inducing immune tolerance, have been successfully produced in plant systems as biologically active and functional therapeutics, demonstrating the broad utility of plant-based platforms across multiple therapeutic classes. This review provides a comprehensive overview of current plant-based production platforms, including whole-plant and plant cell suspension systems, and evaluates their comparative advantages and limitations relative to mammalian expression technologies. Recent progress in the development of therapeutic proteins, with an emphasis on monoclonal antibodies for passive immunization, is highlighted. Finally, the remaining technical, regulatory, and commercial challenges are discussed, along with future prospects for integrating plant-based systems into mainstream biopharmaceutical manufacturing.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"957-977"},"PeriodicalIF":8.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13632707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioDrugsPub Date : 2026-11-01Epub Date: 2026-09-11DOI: 10.1007/s40259-026-00802-z
Martha Caterina Faraguna, Daniël A M Lambregts, Ina Barzel, Edwin H Jacobs, Marianne Hoogeveen-Westerveld, Nadine A M E van der Beek, W W M Pim Pijnappel, Serena Gasperini, Tim Preijers, Johanna M P van den Hout, Ans T van der Ploeg
{"title":"The Effect of Anti-drug Antibodies on the Bioavailability of Alglucosidase Alfa in Classic Infantile Pompe Disease.","authors":"Martha Caterina Faraguna, Daniël A M Lambregts, Ina Barzel, Edwin H Jacobs, Marianne Hoogeveen-Westerveld, Nadine A M E van der Beek, W W M Pim Pijnappel, Serena Gasperini, Tim Preijers, Johanna M P van den Hout, Ans T van der Ploeg","doi":"10.1007/s40259-026-00802-z","DOIUrl":"10.1007/s40259-026-00802-z","url":null,"abstract":"<p><strong>Background: </strong>The impact of anti‑drug antibodies (ADAs) on the bioavailability of recombinant human acid α-glucosidase (rhGAA) in classic infantile Pompe disease remains incompletely understood.</p><p><strong>Objective: </strong>The aim of this study was to investigate the effects of ADAs on the bioavailability of rhGAA in classic infantile Pompe disease.</p><p><strong>Methods: </strong>We analyzed 15 pharmacokinetic (PK) curves from 13 patients receiving rhGAA. High titers were defined as ≥ 1:31250. Alpha-glucosidase activity in plasma was measured using protein A beads to precipitate ADA-bound rhGAA, and sepharose as control. Neutralizing effects were assessed in fibroblasts and culture medium after incubation with patient sera and a fixed amount of rhGAA. Peak activity (C<sub>max</sub>) and area under the curve (AUC) were calculated by non-compartmental analysis.</p><p><strong>Results: </strong>rhGAA bioavailability was affected in six of nine high-titer patients (n = 1, 1:31,250; n = 5, ≥ 1:156,250). AUC was reduced by 11-52% in the protein A assay compared with sepharose (n = 5). Fibroblast uptake studies demonstrated neutralizing effects with intracellular enzyme activity reduced to 47-71% (n = 5). No ADA effect was detectable in three patients. At the group level, high-ADA patients showed significantly lower C<sub>max</sub> in both assays and a lower AUC in the protein A assay compared with non-high-ADA patients. Slower infusion schemes, as management for infusion-associated reactions, correlated inversely with C<sub>max</sub> (R = - 0.64), but not AUC. Immunomodulation eliminated the effects of ADAs, as shown in two patients.</p><p><strong>Conclusions: </strong>High ADAs have heterogenous effects on rhGAA bioavailability. Titers ≥1:156,250, mostly, had a measurable effect, capturing up to > 50% of infused rhGAA. A high titer, per se, did not imply neutralizing effects. Where available, functional assays, including PK curves and uptake studies, may contribute to characterize ADA effects.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"1055-1067"},"PeriodicalIF":8.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioDrugsPub Date : 2026-11-01Epub Date: 2026-09-14DOI: 10.1007/s40259-026-00808-7
Ted R Mikuls, Tuhina Neogi, Angelo Gaffo
{"title":"Beyond the Prevention of Anti-drug Antibody Formation with Uricase Therapy: Mechanistic Roles of DMARDs in Modifying Gout Flare Risk.","authors":"Ted R Mikuls, Tuhina Neogi, Angelo Gaffo","doi":"10.1007/s40259-026-00808-7","DOIUrl":"10.1007/s40259-026-00808-7","url":null,"abstract":"<p><p>Disease-modifying antirheumatic drugs (DMARDs) are immune-modifying agents that have shown efficacy in improving response rates and reducing infusion reactions associated with uricase therapy for uncontrolled gout by inhibiting anti-drug antibody (ADA) formation. However, increased gout flare rates following initiation of uricase therapy remain a concern, impacting patient quality of life and treatment adherence. Gout flares are an acute inflammatory reaction to monosodium urate crystals, driven by inflammasome activation. As such, it is possible that DMARDs could impact gout flare risk. In this hypothesis-generating narrative review, we have synthesized mechanistic data investigating the effects of the DMARDs methotrexate, mycophenolate mofetil, azathioprine, leflunomide, and sirolimus on mechanisms involved in gout flare such as NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activation. The mechanisms by which DMARDs inhibit ADA formation appear to be distinct from those that may affect gout flares, but these may exist in balance with one another to form a distinct pharmacological profile for each agent. Paradoxically, preclinical evidence suggests that DMARDs may sometimes induce NLRP3 inflammasome activation, particularly at higher doses. We suggest that individual DMARDs' effect on inflammatory pathways relevant to gout flare may vary depending on the pathophysiological context and differences in their pharmacological profiles. Therefore, the inflammatory consequences of combining DMARDs with uricase therapy are likely to be specific to the individual agent. Understanding the mechanistic profile of each DMARD is key to optimizing both immunogenicity management and flare outcomes in patients receiving uricase therapy for uncontrolled gout.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"1007-1023"},"PeriodicalIF":8.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioDrugsPub Date : 2026-11-01DOI: 10.1007/s40259-026-00813-w
Matthew J Slarve, Christine Tkaczyk, Michael P Doyle, Timothy J Break, Alexander B Smith, Galit Alter, Brian Luna, Brad Spellberg, Antonio DiGiandomenico
{"title":"Correction: Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.","authors":"Matthew J Slarve, Christine Tkaczyk, Michael P Doyle, Timothy J Break, Alexander B Smith, Galit Alter, Brian Luna, Brad Spellberg, Antonio DiGiandomenico","doi":"10.1007/s40259-026-00813-w","DOIUrl":"10.1007/s40259-026-00813-w","url":null,"abstract":"","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"1093-1094"},"PeriodicalIF":8.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149285076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sustained Efficacy and Safety of Mirikizumab Through 152 Weeks in Chinese Patients with Moderately to Severely Active Crohn's Disease: A Subpopulation Analysis of the VIVID-1 and VIVID-2 Phase 3 Trials.","authors":"Xiang Gao, Qian Cao, Xiaowei Liu, Baili Chen, Wenjia Liu, Wen Tang, Yufang Wang, Jie Zhong, Zhaotao Li, Xiaoyan Wang, Yi Sun, Prashant Gupta, Jiao Yu, Jiawei Xu, Minhu Chen","doi":"10.1007/s40259-026-00810-z","DOIUrl":"10.1007/s40259-026-00810-z","url":null,"abstract":"<p><strong>Background and aim: </strong>Mirikizumab was approved in China for the treatment of Crohn's disease (CD) in 2026. This study evaluated the induction and long-term maintenance of continuous mirikizumab treatment for up to 152 weeks in Chinese patients with moderately to severely active CD.</p><p><strong>Methods: </strong>This was a post hoc, exploratory, and descriptive subpopulation analysis of Chinese patients from the VIVID program, where patients with moderately to severely active CD received intravenous (IV) mirikizumab induction followed by subcutaneous (SC) maintenance dosing. At week 52, endoscopic responders continued SC dosing, while non-responders received IV re-induction at VIVID-2 entry, then resumed SC dosing. Key efficacy endpoints included clinical response by Patient-Reported Outcome, endoscopic response, clinical remission, biomarkers, and quality-of-life-related endpoints. Safety was assessed through week 152 (starting from VIVID-1).</p><p><strong>Results: </strong>In VIVID-1, 164 Chinese patients were randomized and received study treatment; 152 patients with simple endoscopic score for Crohn's disease ≥ 7 (or ≥ 4 for isolated ileal disease) were included in the primary analysis set (PAS). Among the PAS population, 83, 40, and 29 patients received mirikizumab, ustekinumab, and placebo, respectively. At week 52, the mirikizumab-treated group achieved higher endoscopic response-composite (37.3% vs. 0%) and Crohn's Disease Activity Index (CDAI) clinical remission-composite (41.0% vs. 6.9%) than placebo (p < 0.001), and higher efficacy rates than ustekinumab. A greater decrease in C-reactive protein and fecal calprotectin from baseline was observed through week 52 in mirikizumab versus ustekinumab. In VIVID-2, efficacy was sustained through week 152 among endoscopic responders, including CDAI remission (88.5%) and corticosteroid-free CDAI (88.5%). Among endoscopic non-responders, 45.5% regained endoscopic response at week 104 following IV re-induction, with CDAI remission rates of 94.1% at week 152. No unexpected safety findings were observed in the Chinese subpopulation, and the overall VIVID program reported a safety profile consistent with the global population.</p><p><strong>Conclusions: </strong>In Chinese patients with moderately to severely active CD, mirikizumab demonstrated favorable efficacy and safety as both induction and long-term maintenance therapy, consistent with the global population, supporting its potential as a long-term therapeutic option in China. VIVID-1: NCT03926130; VIVID-2: NCT04232553.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"1041-1053"},"PeriodicalIF":8.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149285149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioDrugsPub Date : 2026-11-01Epub Date: 2026-09-19DOI: 10.1007/s40259-026-00803-y
Björn Capsius, Marija Pesic, Ravil Niyazov, Susanne Pippig, Michael Trieb, Rahul Hole, Sigrid Balser, Andreas Seidl
{"title":"From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate.","authors":"Björn Capsius, Marija Pesic, Ravil Niyazov, Susanne Pippig, Michael Trieb, Rahul Hole, Sigrid Balser, Andreas Seidl","doi":"10.1007/s40259-026-00803-y","DOIUrl":"10.1007/s40259-026-00803-y","url":null,"abstract":"<p><p>Regulatory science increasingly recognizes that comparative efficacy studies may provide limited additional certainty to biosimilar development when high-resolution analytical, functional, and pharmacokinetic data robustly demonstrate similarity to the reference product. Modern structural and functional assays, combined with sensitive pharmacokinetic studies are capable of detecting differences with greater sensitivity than clinical efficacy endpoints. Accordingly, recent European Medicines Agency, US Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, and Health Canada guidance suggest increasing alignment toward a \"fit-for-purpose\" pharmacokinetic-anchored clinical approach for biologics with well-characterizable structure and function. Pembrolizumab biosimilar development represents an early real‑world implementation of a streamlined clinical development approach. Its mechanism of action is well understood and driven by programmed cell death protein 1 (PD-1) receptor blockade with minimal reliance on fragment crystallizable-mediated effector functions, and its analytical traceability enables a detailed structure-function characterization. For this molecule, comparative pharmacokinetics provides a sensitive clinical measure of similarity that may be assessed in a multiple-dose pharmacokinetic equivalence study conducted in a sensitive patient population receiving adjuvant treatment following tumor resection. The comparative pharmacokinetic study design also provides a scientifically justified framework to assess safety and immunogenicity. In the development program of the pembrolizumab biosimilar candidate FYB206, scientific reasoning is used to illustrate how tailored pharmacokinetic-centered programs can maintain scientific rigor while reducing unnecessary clinical burden. More broadly, this approach may be considered applicable to other biologics with a well-defined mechanism of action, robust analytical accessibility, and sensitive functional assays, enabling scientifically proportionate and efficient biosimilar development. As FYB206 has not yet received regulatory approval; considerations presented herein reflect a forward‑looking scientific perspective based on the totality of available evidence.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"949-955"},"PeriodicalIF":8.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149007747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}